Acharya, K.R. and Lloyd, M.D. 2005. The advantages and limitations of protein crystal structures. Trends Pharmacol. Sci. 26:10-14.
Brange, J. et al. 1988. Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-682.
Davis, A.M. et al. 2003. Applications and limitations of x-ray crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. 42:2718-2736. Hansen, K.B. et al. 2007. Structural aspects of AMPA receptor activation, desensitization and deactivation.
Curr. Oprin. Neurobiol. 17:281-288. Hardy, L.W. and Malikayil, A. 2003. The impact of structure-guided drug design on clinical agents. Curr. Drug Discov. 3:15-20.
Lam, P.Y.S. et al. 1994. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263:380-384.
McCusker, E.C. et al. 2007. Heterologous GPCR expression: A bottleneck to obtaining crystal structures.
Biotechnol. Prog. 23:540-547. Russell, R.J. et al. 2006. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45-49. Thornton, J.M. et al. 2000. From structure to function: Approaches and limitations. Nat. Struct. Biol. 7:991-994.
von Itzstein, M. et al. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
Was this article helpful?